A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity Lesley SeymourElizabeth Eisenhauer Review 06 December 2000 Pages: 2 - 10
Use of 5-FU plus hyperbaric oxygen for treating malignant tumors: evaluation of antitumor effect and measurement of 5-FU in individual organs Nobuhiro TakiguchiNorio SaitoNobuyuki Nakajima Original Article 14 November 2000 Pages: 11 - 14
Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia Ricardo BellottAnne AuvrignonJacques Robert Original Article 16 November 2000 Pages: 15 - 21
The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin Keiichi FujiwaraHideaki YamauchiIchiro Kohno Original Article 15 November 2000 Pages: 22 - 26
The absorption of retinoic acids from the gastrointestinal tract is dependent upon chemical structure Cheryl L. ZimmermanShaomei HanTimothy S. Wiedmann Original Article 25 November 2000 Pages: 27 - 33
Suppression of tumor growth and metastasis by dietary fish oil combined with vitamins E and C and cisplatin Daniel YamAlpha PeledMeir Shinitzky Original Article 16 November 2000 Pages: 34 - 40
Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates Elizabeth FoxRobert F. MurphyPeter C. Adamson Original Article 07 November 2000 Pages: 41 - 44
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer Kyriakos P. PapadopoulosMerrill J. EgorinCharles S. Hesdorffer Original Article 07 November 2000 Pages: 45 - 50
Differences in intracellular sites of action of Adriamycin in neoplastic and normal differentiated cells Ken-ichi KiyomiyaSaburou MatsuoMasaru Kurebe Original Article 07 November 2000 Pages: 51 - 56
Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial Manuela SchmidingerAlexandra C. BudinskyGuenther G. Steger Original Article 25 November 2000 Pages: 57 - 62
Inactivation of O 6-alkylguanine-DNA alkyltransferase by 8-substituted O 6-benzylguanine analogs in mice Reginald B. EwesuedoLynette R. WilsonM. Eileen Dolan Original Article 09 November 2000 Pages: 63 - 69
Dose schedule of recombinant murine thrombopoietin prior to myelosuppressive and myeloablative therapy in mice Eric G. StefanichCatherine Carlson-ZermenoPaul J. Fielder Original Article 07 November 2000 Pages: 70 - 77
A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents Willi KreisDaniel R. BudmanAnthony Calabro Original Article 07 November 2000 Pages: 78 - 82
A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors Charles W. TaylorRobert T. DorrSydney E. Salmon Original Article 07 November 2000 Pages: 83 - 88
Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction Jon D. HerringtonJose A. FigueroaClinton F. Stewart Clinical Trial Report 22 November 2000 Pages: 89 - 93